Core Viewpoint - YS Biopharma Co., Ltd. has appointed six new members to its Board of Directors, effective February 13, 2024, and elected Dr. Ajit Shetty as Chairperson of the Board [1] Group 1: New Board Members - Dr. Yuntao Cui brings over 15 years of legal experience, previously serving as Senior Lawyer at Zhong Lun Law Firm and General Manager of Legal Affairs at Wanda Group [2] - Dr. Jin Wang, with over 27 years in biotech, is the Founding Partner and CEO of Manhattan Capital Investment Consulting Group and has managed the Nuokang Venture Fund since 2014 [3] - Mr. Henry Chen is the CEO of Monument Pacific Development Corp., focusing on residential and commercial property development in California [4] - Mr. Haitao Zhao has been a Partner at Shanxi Tie Niu law firm since 2016, specializing in corporate law and intellectual property [4] - Mr. Pierson Yue Pan has served as Vice President of Monument Pacific Development Corp. since 2018, with prior experience in project development and management [5] - Ms. Chunyuan (Brenda) Wu has been the CFO of YS Group since December 31, 2020, with extensive experience in finance and auditing [5] Group 2: Leadership Comments - Dr. Ajit Shetty expressed confidence in the new directors, highlighting their expertise in corporate governance, legal affairs, business management, and strategic decision-making [6] Group 3: Company Overview - YS Biopharma is a global biopharmaceutical company focused on developing vaccines and therapeutic biologics for infectious diseases and cancer, utilizing its proprietary PIKA® immunomodulating technology platform [7]
YS Biopharma Announces Appointment of New Directors